TY - JOUR T1 - Epidemiology of the early COVID-19 epidemic in Orange County, California: comparison of predictors of test positivity, mortality, and seropositivity JF - medRxiv DO - 10.1101/2021.01.13.21249507 SP - 2021.01.13.21249507 AU - Daniel M. Parker AU - Tim Bruckner AU - VerĂ³nica M. Vieira AU - Catalina Medina AU - Vladimir N. Minin AU - Philip L. Felgner AU - Alissa Dratch AU - Matthew Zahn AU - Scott M. Bartell AU - Bernadette Boden-Albala Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/18/2021.01.13.21249507.abstract N2 - COVID-19 is one of the largest public health emergencies in modern history. Here we present a detailed analysis from a large population center in Southern California (Orange County, population of 3.2 million) to understand heterogeneity in risks of infection, test positivity, and death. We used a combination of datasets, including a population-representative seroprevalence survey, to assess the true burden of disease as well as COVID-19 testing intensity, test positivity, and mortality. In the first month of the local epidemic, case incidence clustered in high income areas. This pattern quickly shifted, with cases next clustering in much higher rates in the north-central area which has a lower socio-economic status. Since April, a concentration of reported cases, test positivity, testing intensity, and seropositivity in a north-central area persisted. At the individual level, several factors (e.g., age, race/ethnicity, zip codes with low educational attainment) strongly affected risk of seropositivity and death.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe serological survey was funded through a contract with OCHCA (MA-042-20011978).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This analysis includes a retrospective analysis of de-identified, anonymized epidemiological records. The UCI Institutional Review Board (IRB) reviewed the details of this study, provided written confirmation that this study is not considered human subjects research, and that the study has been waived from ethics approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData on reported cases and deaths came from the Orange County Health Care Agency (OCHCA). These data can be requested directly through OCHCA: Alissa Dratch: adratch{at}ochca.com The serological data can be requested directly from the PI or MPI of that project: Dr Tim Bruckner: tim.bruckner{at}uci.edu Dr Bernadette Boden-Albala: bbodenal{at}uci.edu https://github.com/CatalinaMedina/oc-positivity-plus ER -